$183 Million

Arcutis Biotherapeutics, Inc.

Initial Public Offering

Bookrunner, January 2020

Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company’s current portfolio is comprised of topical treatments with significant potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology.